Fabry Disease: all 246 studies
Page 2 of 3. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.
- A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry DiseaseCompletedNCT00140621Phase 4Results posted
- Replagal Enzyme Replacement Therapy for Children With Fabry DiseaseCompletedNCT00084084Phase 2Results posted
- A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry DiseaseCompletedNCT00081497Phase 4Results posted
- A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry DiseaseCompletedNCT00074984Phase 4Results posted
- A Study of Fabrazyme in Pediatric Patients With Fabry DiseaseCompletedNCT00074958Phase 2Results posted
- Dosing Study of Replagal in Patients With Fabry DiseaseCompletedNCT00068107Phase 2Results posted
- Evaluation of the Effect of a Low-FODMAP Diet on Gastrointestinal Symptoms and Inflammatory Markers in Fabry PatientsActive, not recruitingNCT07888998Not applicable
- Natural History in Fabry Disease With IVS4+919G>A MutationsActive, not recruitingNCT07506083
- Anderson Fabry Disease - the Power of Information.CompletedNCT07136662Not applicable
- RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)CompletedNCT06935578
- Diagnostic Role of Renal Biopsy in Patients With Fabry DiseaseCompletedNCT06801288
- A Real-world Wearables Study in Fabry Disease.CompletedNCT06484478
- Real World Evidence Study of Danish Fabry PatientsActive, not recruitingNCT06303466
- A Co-designed Physical Activity Intervention in Fabry DiseaseCompletedNCT06257901
- German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfaActive, not recruitingNCT06095713
- Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in TaiwanActive, not recruitingNCT06052800
- Autoimmune and Inflammatory Response Biomarkers in Fabry DiseaseCompletedNCT06007768
- T1 Mapping in Fabry DiseaseCompletedNCT05923788Not applicable
- FASHION Fabry Disease Hypertrophic Cardiomyopathy and InfammationStatus unknownNCT05761834
- Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease PatientsStatus unknownNCT05710367Phase 2
- Cardiovasculorenal Phenotyping in Fabry Disease Through Noninvasive TestingTerminatedNCT05699265
- A Qualitative Study on the Pain and Quality of Life of Patients With Fabry DiseaseStatus unknownNCT05679076
- Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)CompletedNCT05671770
- Screening of Fabry Disease in Portuguese Patients With Idiopathic CardiomyopathiesCompletedNCT05409846
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseActive, not recruitingNCT05280548Phase 3
- A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry DiseaseActive, not recruitingNCT05206773Phase 3
- Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly InfusionCompletedNCT05186324
- Early Detection of Fabry DiseaseCompletedNCT05106764
- Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease PatientsStatus unknownNCT05056636
- China Post-marketing Surveillance (PMS) Study of Fabrazyme®CompletedNCT05054387Phase 4
- Studying Lipids as Potential Biomarkers in Patients With Fabry DiseaseCompletedNCT05046379
- Long-Term Follow-up of Subjects Who Were Treated With ST-920Active, not recruitingNCT05039866
- Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201TerminatedNCT04999059
- Fabry Aim Children Early (ACE) ProjectWithdrawnNCT04965467
- Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical ScoreActive, not recruitingNCT04943991Not applicable
- Global Burden and Treatment Trajectiories in Italian Patients With Fabry DiseaseCompletedNCT04916977
- Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.Status unknownNCT04893889Not applicable
- Early Detection and Follow-Up of Patients With Fabry's DiseaseStatus unknownNCT04847713
- Understanding Fabry Disease Therapy Choices Through the Eyes of the PatientsCompletedNCT04804566
- Getting Global Rare Disease Insights Through Technology StudyStatus unknownNCT04758130Not applicable
- Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease CardiomyopathyStatus unknownNCT04724083
- Characterisation of Heart Involvement in Fabry Disease With T1 MappingCompletedNCT04708301
- French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With MigalastatCompletedNCT04602364
- Pulsatility Index, Vasomotor Reactivity and Leukoencephalopathy in Fabry PatientsCompletedNCT04577170
- Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease PatientsApproved for marketingNCT04552691
- An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry DiseaseActive, not recruitingNCT04519749Phase 1/2
- Complement Activation in the Lysosomal Storage DisordersWithdrawnNCT04189601
- Screening of Fabry Disease in Patients With GI SymptomsStatus unknownNCT04184986
- To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry DiseaseWithdrawnNCT04143958Phase 4
- Study of the Spermatic Characteristics of Patients With Fabry DiseaseTerminatedNCT04073888Not applicable
- Therapeutic Exercise to Treat Neuropathic PainCompletedNCT04050137Not applicable
- Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and PreferencesCompletedNCT04043273
- Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased IndividualsStatus unknownNCT04025801
- A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseActive, not recruitingNCT04020055Phase 3
- A Study of Migalastat in Fabry DiseaseActive, not recruitingNCT03949920
- Screening for Fabry Disease in Renal TransplantationTerminatedNCT03886714
- Effect of Migalastat on Cardiac Involvement in Fabry DiseaseCompletedNCT03838237
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseActive, not recruitingNCT03737214Phase 3
- MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational StudyStatus unknownNCT03683966
- Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry DiseaseCompletedNCT03678324Not applicable
- Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease PatientsCompletedNCT03614234Phase 3
- Epidemiological Study of Fabry Disease in Taiwan Young Stroke PatientsStatus unknownNCT03596398
- Diagnostic Value of the Electrocardiogram in Fabry DiseaseStatus unknownNCT03362645
- Kidney Information Network for Disease Research and EducationTerminatedNCT03321604
- Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry DiseaseActive, not recruitingNCT03305250Not applicable
- Fabry Outcome Survey (FOS)CompletedNCT03289065
- Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's CardiomyopathyStatus unknownNCT03230591
- Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber NeuropathyCompletedNCT03230149
- Safety and Effect of Oral RVX000222 in Subjects With Fabry DiseaseWithdrawnNCT03228940Phase 1/2
- Natural History in Fabry Patients With IVS4+919G>A MutationStatus unknownNCT03222336
- Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare DiseasesStatus unknownNCT03199001
- Evaluation of Phenotypic Variability in Fabry DiseaseWithdrawnNCT03145779
- German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.CompletedNCT03135197
- Study of the Relation Between Lipid Myocardial Overload Evaluated by Cardiac Magnetic Resonance Imaging (MRI), Alteration of Longitudinal Myocardial Deformations by Echocardiography, and Clinical Achievements (Functional, Biological and Electrical) in Fabry Disease, and Its Outcomes.Status unknownNCT03123523
- Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry DiseaseCompletedNCT02995993Phase 1
- Podocyturia - Predictor of Renal Dysfunction in Fabry NephropathyStatus unknownNCT02994303
- Fabry: Renal Function During Long-term ERT by 51Cr-EDTA ClearanceCompletedNCT02969200
- Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry DiseaseCompletedNCT02956954Not applicable
- A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry DiseaseCompletedNCT02930655Phase 1
- Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry DiseaseWithdrawnNCT02921620Phase 3
- Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement TherapyCompletedNCT02908724
- Diagnosis of Fabry Disease: Impact of an Educational Brochure Intended for CardiologistStatus unknownNCT02883205
- Fabry Disease in Cerebrovascular DiseaseStatus unknownNCT02859363
- Study of the Prevalence of Fabry Disease in French Dialysis PatientsStatus unknownNCT02843334
- Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry DiseaseCompletedNCT02800070Phase 1
- Biomarker for Patients With Fabry Disease (BioFabry)WithdrawnNCT02778295
- Fabry Disease Screening in ESRD Patients in West of FranceCompletedNCT02719249
- Lipidomics and Functional Analyses of Platelets in Fabry DiseaseStatus unknownNCT02649660
- Fabry's Disease and Pregnancy (PREFAB)TerminatedNCT02582294
- Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)Status unknownNCT02469181
- Prevalence of Fabry's Disease in a Population of Patients With Chronic PainCompletedNCT02450604Not applicable
- Screening for Fabry Disease in a Pediatric Population at RiskCompletedNCT02152189
- Investigating Lysosomal Storage Diseases in Minority GroupsStatus unknownNCT02120235
- Paricalcitol in Fabry DiseaseCompletedNCT02090608Not applicable
- A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy VolunteersCompletedNCT02082327Phase 1
- Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.CompletedNCT01997489Phase 4
- Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.CompletedNCT01947634Not applicable
- A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese SubjectsCompletedNCT01853852Phase 1
- A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry DiseaseTerminatedNCT01839526Phase 1
- Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase BetaCompletedNCT01745185